Biolife4D

BIOLIFE4D is a biotechnology company based in Buffalo Grove, Illinois, that specializes in 3D bioprinting technology to develop synthetic human organs, particularly hearts. The company's core mission is to create patient-specific, fully functioning hearts through 3D bioprinting using a patient's own cells. This approach aims to eliminate the challenges of organ rejection and long donor waiting lists associated with conventional organ transplant methods.

BIOLIFE4D's process begins with obtaining cells from a patient's blood sample, which are then reprogrammed into induced pluripotent stem cells (iPSCs). These iPSCs are subsequently differentiated into various types of cardiac cells required for bioprinting individual heart components. Using advanced 3D modeling software and a proprietary bio-ink containing the patient's cells and undisclosed nutrients, the company bioprints a digital replica of the patient's heart. The bioprinted structure is then incubated in a bioreactor, allowing the cells to self-organize, fuse into living tissues, and eventually start beating in unison.

As a precursor to developing a full-scale organ replacement product, BIOLIFE4D is currently focusing on producing a functional mini-heart for cardiotoxicity testing. This mini-heart aims to have four chambers, valves, greater vessels, musculature, electrical activity, and the ability to generate intraluminal pressures. The company has also developed stem cell-derived mitral and aortic heart valves to replace damaged valves in patients, potentially eliminating the need for blood thinners.

In June 2018, BIOLIFE4D successfully demonstrated the ability to 3D print human heart tissue, marking a significant milestone in its research efforts. By June 2019, the company had bioprinted a miniature human heart, becoming the first company to achieve this feat. Additionally, BIOLIFE4D has signed a collaboration agreement with Bayer AG to test new drugs on its 3D-printed human heart tissue, aiming to address early assessment of drug candidates' safety and tolerability.